Chiome Bioscience Inc. provided earnings guidance for 2023. For the period, the company expects net sales of ¥640 million in the drug discovery support business.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
123 JPY | -2.38% | -3.91% | -8.89% |
Apr. 01 | Chiome Bioscience Cancels License Agreements with ADC Therapeutics | MT |
Feb. 13 | Chiome Bioscience Inc. Announces Entrustment Agreement with Takeda Pharmaceutical Company Limited | CI |
1st Jan change | Capi. | |
---|---|---|
-8.89% | 44.54M | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- 4583 Stock
- News Chiome Bioscience Inc.
- Chiome Bioscience Inc. Provided Sales Guidance for 2023